Sarah E Baum1, Kari White2, Kristine Hopkins3, Joseph E Potter3, Daniel Grossman4. 1. Texas Policy Evaluation Project, Austin, TX; Ibis Reproductive Health, Oakland, CA. Electronic address: sbaum@ibisreproductivehealth.org. 2. Texas Policy Evaluation Project, Austin, TX; Department of Health Care Organization and Policy, School of Public Health, University of Alabama at Birmingham, Birmingham, AL. 3. Texas Policy Evaluation Project, Austin, TX; Population Research Center, University of Texas at Austin, Austin, TX. 4. Texas Policy Evaluation Project, Austin, TX; Advancing New Standards in Reproductive Health (ANSIRH), Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, Oakland, CA.
Abstract
BACKGROUND: In 2013, Texas House Bill 2 (HB 2) placed restrictions on the use of medication abortion, which later were nullified with the 2016 FDA-approved mifepristone label. METHODS: Using data collected directly from Texas abortion facilities, we evaluated changes in the provision and use of medication abortion during three 6-month time periods corresponding to the policy changes: before HB 2, after HB 2 and after the label change. RESULTS: Medication abortion constituted 28% of all abortions before HB 2, 10% after implementation of the restrictions and 33% after the label change. CONCLUSIONS: Use of medication abortion in Texas rebounded after the FDA label change.
BACKGROUND: In 2013, Texas House Bill 2 (HB 2) placed restrictions on the use of medication abortion, which later were nullified with the 2016 FDA-approved mifepristone label. METHODS: Using data collected directly from Texas abortion facilities, we evaluated changes in the provision and use of medication abortion during three 6-month time periods corresponding to the policy changes: before HB 2, after HB 2 and after the label change. RESULTS: Medication abortion constituted 28% of all abortions before HB 2, 10% after implementation of the restrictions and 33% after the label change. CONCLUSIONS: Use of medication abortion in Texas rebounded after the FDA label change.
Authors: Daniel Grossman; Sarah Baum; Liza Fuentes; Kari White; Kristine Hopkins; Amanda Stevenson; Joseph E Potter Journal: Contraception Date: 2014-07-22 Impact factor: 3.375
Authors: Caitlin Gerdts; Liza Fuentes; Daniel Grossman; Kari White; Brianna Keefe-Oates; Sarah E Baum; Kristine Hopkins; Chandler W Stolp; Joseph E Potter Journal: Am J Public Health Date: 2016-03-17 Impact factor: 11.561
Authors: Sarah Raifman; Gracia Sierra; Daniel Grossman; Sarah E Baum; Kristine Hopkins; Joseph E Potter; Kari White Journal: Contraception Date: 2021-03-21 Impact factor: 3.051
Authors: Vinita Goyal; Isabel H McLoughlin Brooks; Robin Wallace; Amna I Dermish; Bhavik Kumar; Ann Schutt-Ainé; Anitra Beasley; Abigail R A Aiken; Joseph E Potter Journal: Am J Obstet Gynecol Date: 2020-02-25 Impact factor: 10.693
Authors: Liza Fuentes; Sarah Baum; Brianna Keefe-Oates; Kari White; Kristine Hopkins; Joseph Potter; Daniel Grossman Journal: BMC Womens Health Date: 2020-01-06 Impact factor: 2.809